Median (range) | 68 (34–85) |
Sex | |
Male | 22 (73) |
Female | 8 (27) |
Primary tumour | |
Colon | 16 (53) |
Rectum | 14 (47) |
ECOG performance status | |
0 | 18 (60) |
1 | 9 (30) |
2 | 3 (10) |
Liver metastases | |
Unilobar | 17 (57) |
Bilobar | 13 (43) |
≤ 4 lesions | 19 (63) |
> 4 lesions | 11 (37) |
Previous chemotherapy | |
Yes | 17 (57) |
No | 13 (43) |
Age ≤ 65 years | 11 (37) | 15.2 | 8.5–21.8 | 0.284 |
Age > 65 years | 19 (63) | 21.6 | 4.7–38.4. | |
Colon | 16 (53) | 23.7 | 16.8–30.5 | 0.145 |
Rectum | 14 (47) | 14.1 | 6.8–21.4 | |
ECOG 0 | 18 (60) | 19.8 | 11.3–28.4 | 0.805 |
ECOG 1 or 2 | 12 (40) | 17.4 | 10.0–29.7 | |
Previous chemotherapy | 17 (57) | 17.4 | 11.0–23.7 | 0.472 |
No previous chemotherapy | 13 (43) | 21.6 | 3.8–39.4 | |
Unilobar disease | 17 (57) | 23.5 | 7.4–39.6 | 0.106 |
Bilobar disease | 13 (43) | 15.2 | 1.9–28.4 | |
≤ 4 liver lesions | 19 (63) | 15.5–31.5 | ||
> 4 liver lesions | 11 (37) | 0.3–21.3 | ||
CEA ≤ 5 µg/L before the first DEBIRI TACE | 5 (27) | 17.4 | 5.9–28.9 | 0.591 |
CEA > 5 µg/L before the first DEBIRI TACE | 22 (73) | 15.2 | 9.2–21.1 | |
Increase of serum CEA after first DEBIRI TACE | 10 (33) | 14.1 | 7.3–20.9 | 0.037 |
Decrease of serum CEA after first DEBIRI TACE | 12 (40) | 24.7 | 7.0–42.4 | |
CEA stayed the same | 1 (3) | 25.5 | ||
CA 19-9 ≤ 37 kU/L before first DEBIRI TACE | 16 (53) | 15.2 | 10.1–20.2 | 0.393 |
CA 19-9 > 37 kU/L before first DEBIRI TACE | 11 (47) | 17.4 | 0.5–34.2 | |
Increase of serum CA 19-9 after first DEBIRI TACE | 11 (48) | 15.2 | 11.7–18.7 | 0.583 |
Decrease of serum CA 19-9 after first DEBIRI TACE | 10 (43) | 19.8 | 0.0–44.9 | |
CA 19-9 stayed the same | 2 (9) | 7.4 |